Environmental and behavioral controls of the expression of clozapine tolerance: Evidence from a novel across-model transfer paradigm

Behavioural Brain Research

Volumn 238, Issue 1, 2013, Pages 178-187

  Feng, Min ^a,b,c   Sui, Nan ^a   Li, Ming ^b  

^a INSTITUTE OF PSYCHOLOGY   (China)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Clozapine; Conditioned avoidance response; Contextual control; Motor activity; Phencyclidine; Tolerance

Indexed keywords

CLOZAPINE;

ADAPTIVE BEHAVIOR; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR CHANGE; BEHAVIOR CONTROL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERANCE; EVIDENCE BASED MEDICINE; INHIBITION (PSYCHOLOGY); LOCOMOTION; MALE; MOTOR ACTIVITY; NEUROPHYSIOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; TASK PERFORMANCE;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CONDITIONING (PSYCHOLOGY); DRUG TOLERANCE; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84868561290     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.10.009     Document Type: Article

References (50)

1. Zhang C., Li M. Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine. Behavioural Pharmacology 2012, 23:66-79.
2. Meltzer H.Y., Bastani B., Kwon K.Y., Ramirez L.F., Burnett S., Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Berl) 1989, 99(Suppl.):S68-S72.
3. Chakos M., Lieberman J., Hoffman E., Bradford D., Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry 2001, 158:518-526.
4. Nasrallah H.A., Meyer J.M., Goff D.C., McEvoy J.P., Davis S.M., Stroup T.S., et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research 2006, 86:15-22.
5. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988, 45:789-796.
6. Seeman P., Schwarz J., Chen J.F., Szechtman H., Perreault M., McKnight G.S., et al. Psychosis pathways converge via D2high dopamine receptors. Synapse 2006, 60:319-346.
7. Rebec G.V., Peirson E.E., McPherson F.A., Brugge K. Differential sensitivity to amphetamine following long-term treatment with clozapine or haloperidol. Psychopharmacology (Berl) 1982, 77:360-366.
8. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. Journal of Neurochemistry 1990, 54:1755-1760.
9. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 1992, 46:315-328.
10. Mead A., Li M. Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism. Journal of Psychopharmacology 2010, 24:1045-1053.
11. Li M., Sun T., Zhang C., Hu G. Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning. Psychopharmacology (Berl) 2010, 212:45-57.
12. Swalve N., Li M. Parametric studies of antipsychotic-induced sensitization in the conditioned avoidance response model: roles of number of drug exposure, drug dose, and test-retest interval. Behavioural Pharmacology 2012, 23:380-391.
13. Li M., Sun T., Mead A. Clozapine, but not olanzapine, disrupts conditioned avoidance response in rats by antagonizing 5-HT(2A/2C) receptors. Journal of Neural Transmission 2012, 119:497-505.
14. Stanford J.A., Fowler S.C. Subchronic effects of clozapine and haloperidol on rats' forelimb force and duration during a press-while-licking task. Psychopharmacology (Berl). 1997, 130:249-253.
15. Trevitt J., Atherton A., Aberman J., Salamone J.D. Effects of subchronic administration of clozapine, thioridazine and haloperidol on tests related to extrapyramidal motor function in the rat. Psychopharmacology (Berl) 1998, 137:61-66.
16. Varvel S.A., Vann R.E., Wise L.E., Philibin S.D., Porter J.H. Effects of antipsychotic drugs on operant responding after acute and repeated administration. Psychopharmacology (Berl) 2002, 160:182-191.
17. Villanueva H.F., Porter J.H. Differential tolerance to the behavioral effects of chronic pimozide and clozapine on multiple random interval responding in rats. Behavioural Pharmacology 1993, 4:201-208.
18. Goudie A.J., Cooper G.D., Cole J.C., Sumnall H.R. Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats. Journal of Psychopharmacology 2007, 21:179-190.
19. Goudie A.J., Cole J.C., Sumnall H.R. Olanzapine and JL13 induce cross-tolerance to the clozapine discriminative stimulus in rats. Behavioural Pharmacology 2007, 18:9-17.
20. Gleason S.D., Shannon H.E. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) 1997, 129:79-84.
21. Natesan S., Reckless G.E., Nobrega J.N., Fletcher P.J., Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D(2) receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 2006, 31:1854-1863.
22. Wadenberg M.L., Hicks P.B. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics. Neuroscience and Biobehavioral Reviews 1999, 23:851-862.
23. Sun T., Hu G., Li M. Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs. European Journal of Pharmacology 2009, 602:334-342.
24. Li M., Parkes J., Fletcher P.J., Kapur S. Evaluation of the motor initiation hypothesis of APD-induced conditioned avoidance decreases. Pharmacology Biochemistry and Behavior 2004, 78:811-819.
25. Li M., He W., Mead A. An investigation of the behavioral mechanisms of antipsychotic action using a drug-drug conditioning paradigm. Behavioural Pharmacology 2009, 20:184-194.
26. Smith J.B. Situational specificity of tolerance to decreased operant responding by morphine and l-nantradol. Psychopharmacology (Berl) 1991, 103:115-120.
27. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. Journal of Pharmacology and Experimental Therapeutics 2003, 305:625-631.
28. Kalinichev M., Robbins M.J., Hartfield E.M., Maycox P.R., Moore S.H., Savage K.M., et al. Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:414-422.
29. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacologica et Toxicologica (Copenh) 1982, 51:321-329.
30. Sanger D.J. The effects of clozapine on shuttle-box avoidance responding in rats: comparisons with haloperidol and chlordiazepoxide. Pharmacology Biochemistry and Behavior 1985, 23:231-236.
31. Mead A., Li M. Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism. Journal of Psychopharmacology 2010, 24:1045-1053.
32. Li M., Fletcher P.J., Kapur S. Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacology 2007, 32:263-272.
33. Stewart J., Badiani A. Tolerance and sensitization to the behavioral effects of drugs. Behavioural Pharmacology 1993, 4:289-312.
34. Corfield-Sumner P.K., Stolerman I.P. Behavioral tolerance. Contemporary research in behavioral pharmacology 1978, 391-448. Plenum Press, New York. D.E. Blackman, D.J. Sanger (Eds.).
35. Chen C.S. A study of the alcohol-tolerance effect and an indtroduction of a new behavioural technique. Psychopharmacologia 1968, 12:433-440.
36. Siegel S., Baptista M.A., Kim J.A., McDonald R.V., Weise-Kelly L. Pavlovian psychopharmacology: the associative basis of tolerance. Experimental and Clinical Psychopharmacology 2000, 8:276-293.
37. Sripada S., Gaytan O., Swann A., Dafny N. The role of MK-801 in sensitization to stimulants. Brain Research. Brain Research Reviews 2001, 35:97-114.
38. Lanis A., Schmidt W.J. NMDA receptor antagonists do not block the development of sensitization of catalepsy, but make its expression state-dependent. Behavioural Pharmacology 2001, 12:143-149.
39. Anagnostaras S.G., Schallert T., Robinson T.E. Memory processes governing amphetamine-induced psychomotor sensitization. Neuropsychopharmacology 2002, 26:703-715.
40. Robinson T.E., Browman K.E., Crombag H.S., Badiani A. Modulation of the induction or expression of psychostimulant sensitization by the circumstances surrounding drug administration. Neuroscience and Biobehavioral Reviews 1998, 22:347-354.
41. Anagnostaras S.G., Robinson T.E. Sensitization to the psychomotor stimulant effects of amphetamine: modulation by associative learning. Behavioral Neuroscience 1996, 110:1397-1414.
42. Browman K.E., Badiani A., Robinson T.E. Modulatory effect of environmental stimuli on the susceptibility to amphetamine sensitization: a dose-effect study in rats. Journal of Pharmacology and Experimental Therapeutics 1998, 287:1007-1014.
43. Chiodo L.A., Bunney B.S. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. The Journal of Neuroscience 1983, 3:1607-1619.
44. Chiodo L.A., Bunney B.S. Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. The Journal of Neuroscience 1985, 5:2539-2544.
45. Coward D.M. General pharmacology of clozapine. British Journal of Psychiatry. Supplement 1992, 17:5-11.
46. Menon M.K., Gordon L.I., Fitten J. Interaction between clozapine and a lipophilic alpha 1-adrenergic agonist. Life Sciences 1988, 43:1791-1804.
47. Millan M.J., Audinot V., Melon C., Newman-Tancredi A. Evidence that dopamine D3 receptors participate in clozapine-induced hypothermia. European Journal of Pharmacology 1995, 280:225-229.
48. Touyz S.W., Saayman G.S., Zabow T. A psychophysiological investigation of the long-term effects of clozapine upon sleep patterns of normal young adults. Psychopharmacology (Berl) 1978, 56:69-73.
49. Seppala N., Kovio C., Leinonen E. Effect of anticholinergics in preventing acute deterioration in patients undergoing abrupt clozapine withdrawal. CNS Drugs 2005, 19:1049-1055.
50. Goudie A.J., Smith J.A., Robertson A., Cavanagh C. Clozapine as a drug of dependence. Psychopharmacology (Berl) 1999, 142:369-374.